Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director · President and CEO | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vistagen Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,846 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 36,818 · Balance 54,846 F1: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP. |
| Common StockSEC Table I · non-derivative | IndirectBy The 1997 Singh Family Trust | 20,875 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,875 F2: Shares held by The 1997 Singh Family Trust U/R/D 05/29/1997. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended (the "ESPP"), in a transaction exempt under Rule 16b-3 and Rule 16b-3(d). The Reporting Person purchased the maximum amount permitted under the ESPP.
F2: Shares held by The 1997 Singh Family Trust U/R/D 05/29/1997.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2017 Filed Sep 20, 2017 20:33 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001415889-17-001522 · form4-09202017_010944.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-09-19 F1 · derivative.exercise_date: 1/3rd of the total number of shares shall be immediately vested upon the Vesting Start Date, 9/19/2017, and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years from the Vesting Start Date. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:31 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-17-000679 · form4-04282017_120423.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-04-26 F1 · derivative.exercise_date: One third (1/3rd) of the total shares shall vest one (1) year following the date of grant and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested three (3) years from the date of grant. Read SEC document |
| November 09, 2016 Filed Nov 11, 2016 01:30 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-16-007386 · form4-11102016_081115.xml · derivative · entry 1 Singh Shawn · CIK 0001412071 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-11-09 F1 · derivative.exercise_date: Options vest monthly over a period of three years commencing November 9, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.